Moderna announced that its cancer vaccine had demonstrated efficacy in a late-stage clinical trial. The combination therapy was confirmed to reduce the risk of recurrence and metastasis, while information was also reported on its co-development with Merck and strong results from other pharmaceutical companies.
The focus of the U.S. market last week was an announcement that Moderna's mRNA-based cancer vaccine had demonstrated efficacy in a late-stage clinical trial by reducing the risk of recurrence and metastasis in melanoma. Investors were particularly interested because this was the first time clinical trial results for a cancer vaccine had been deemed favorable. The possibility that it could outperform Keytruda as a combination therapy was also viewed as a positive factor.
Moderna is co-developing the cancer vaccine with Merck, and efficacy was observed in the latest clinical trial when it was administered in combination with Merck's cancer immunotherapy Keytruda. If the prospects for commercialization become clearer, the vaccine could significantly change the company's viability and its potential future applications.
Meanwhile, Eli Lilly and Amgen each reported strong results related to obesity treatments. Lilly continued to see sales growth for its flagship drug, while Amgen's future development of obesity treatments is attracting attention. These developments are viewed as factors that could affect the growth outlook for the pharmaceutical sector.
The iShares Biotechnology ETF (IBB) was also highlighted and attracted attention as an indicator reflecting trends across biotechnology stocks and market interest.